How do you use Gleevec in a sentence? See 5 example sentences showing how this word appears in different contexts.
Gleevec in a sentence
Context around Gleevec
- Average sentence length in these examples: 21 words
- Position in the sentence: 1 start, 2 middle, 2 end
- Sentence types: 5 statements, 0 questions, 0 exclamations
Corpus analysis for Gleevec
- In this selection, "gleevec" usually appears in the middle of the sentence. The average example has 21 words, and this corpus slice is mostly made up of statements.
- Around the word, drug, imatinib, worked, imatinib and works stand out and add context to how "gleevec" is used.
- Recognizable usage signals include iressa or gleevec works to and patent on gleevec. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "gleevec" sits close to words such as aaas, aacc and aacs, which helps place it inside the broader word index.
Example types with gleevec
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
One such drug, Gleevec, worked spectacularly in patients with chronic myeloid leukemia. (12 words)
On 1 April 2013, it was announced that the Indian court invalidated Novartis's patent on Gleevec. (17 words)
It is treated with imatinib (Gleevec in United States, Glivec in Europe) or other drugs. citation The five-year survival rate is 90%. (23 words)
The addition of agents such as Herceptin, Iressa, or Gleevec works to stop cells from cycling and causes apoptosis activation by blocking growth and survival signaling further upstream. (28 words)
Drugs that inhibit specific kinases are being developed to treat several diseases, and some are currently in clinical use, including Gleevec ( imatinib ) and Iressa ( gefitinib ). (25 words)
It is treated with imatinib (Gleevec in United States, Glivec in Europe) or other drugs. citation The five-year survival rate is 90%. (23 words)
Example sentences (5)
One such drug, Gleevec, worked spectacularly in patients with chronic myeloid leukemia.
Drugs that inhibit specific kinases are being developed to treat several diseases, and some are currently in clinical use, including Gleevec ( imatinib ) and Iressa ( gefitinib ).
It is treated with imatinib (Gleevec in United States, Glivec in Europe) or other drugs. citation The five-year survival rate is 90%.
On 1 April 2013, it was announced that the Indian court invalidated Novartis's patent on Gleevec.
The addition of agents such as Herceptin, Iressa, or Gleevec works to stop cells from cycling and causes apoptosis activation by blocking growth and survival signaling further upstream.